A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis

International Journal of Antimicrobial Agents

Volumn 31, Issue 3, 2008, Pages 240-244

  Roberts, Jason A ^a,b   Roberts, Michael S ^a   Robertson, Thomas A ^a   Cross, Sheree E ^a   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Lactam; Continuous infusion; Microdialysis; Piperacillin; Plasma exchange

Indexed keywords

BETA LACTAM ANTIBIOTIC; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; EXTRACELLULAR FLUID; GUILLAIN BARRE SYNDROME; HUMAN; MALE; MICRODIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; GUILLAIN-BARRE SYNDROME; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICRODIALYSIS; PIPERACILLIN; PLASMA EXCHANGE; PNEUMONIA, VENTILATOR-ASSOCIATED; SERUM; SUBCUTANEOUS TISSUE;

EID: 38949200556     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.09.013     Document Type: Article

References (21)

1. Hughes R.A., and Cornblath D.R. Guillain-Barré syndrome. Lancet 366 (2005) 1653-1666
2. Smith J.W., and Weinstein R. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 43 (2003) 820-822
3. Fauvelle F., Petitjean O., Tod M., and Guillevin L. Clinical pharmacokinetics during plasma exchange. Therapie 55 (2000) 269-275
4. Kintzel P.E., Eastlund T., and Calis K.A. Extracorporeal removal of antimicrobials during plasmapheresis. J Clin Apher 18 (2003) 194-205
5. Roberts J.A., and Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 45 (2006) 755-773
6. Cunha B.A. Antibiotic treatment of sepsis. Med Clin North Am 79 (1995) 551-558
7. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., Jimenez-Jimenez F.J., Perez-Paredes C., and Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31 (2003) 2742-2751
8. Garnacho-Montero J., Garnacho-Montero C., Cayuela A., and Ortiz-Leyba C. Timing of adequate antibiotic therapy is more determinant of outcome than TNF and IL-10 polymorphisms in septic patients. Crit Care 10 (2006) R111
9. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D., et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115 (2003) 529-535
10. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
11. MacArthur R.D., Miller M., Albertson T., Panacek E., Johnson D., Teoh L., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 38 (2004) 284-288
12. Joukhadar C., Frossard M., Mayer B.X., Brunner M., Klein N., Siostrzonek P., et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 29 (2001) 385-391
13. Ryan D.M. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 31 Suppl. D (1993) 1-16
14. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (1992) 1644-1655
15. de la Pena A., Liu P., and Derendorf H. Microdialysis in peripheral tissues. Adv Drug Deliv Rev 45 (2000) 189-216
16. de Lange E.C.M., de Boer A.G., and Breimer D.D. Methodological issues for microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45 (2000) 125-148
17. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
18. McClellan S.D., Whitaker C.H., and Friedberg R.C. Removal of vancomycin during plasmapheresis. Ann Pharmacother 31 (1997) 1132-1136
19. Bakken J.S., Cavalieri S.J., Gangeness D., Kubat T., and Pollack J.R. Influence of therapeutic plasmapheresis on elimination of ceftriaxone. Antimicrob Agents Chemother 37 (1993) 1171-1173
20. Fauvelle F., Lortholary O., Tod M., Guillevin L., Louchahi M., Léon A., et al. Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients. Antimicrob Agents Chemother 38 (1994) 1519-1522
21. Bozkurt F., Schollmeyer P., and Keller E. Kinetics of ceftazidime during plasmapheresis. Eur J Clin Pharmacol 33 (1987) 197-201